We discuss the proposed biomarkers for VHL disease that include monitoring plasma levels of HIF-dependent molecules, such as VEGF, which may allow for the monitoring of disease activity in VHL patients. The gene discussed is VEGFA; the disease is von Hippel-Lindau disease.